Navigation Links
Immediate use of an IUD following abortion more likely to prevent unintended pregnancies
Date:6/8/2011

PORTLAND, Ore. Women who receive a contraceptive known as an intrauterine device or IUD immediately following a first trimester abortion experience few complications and are less likely to have an unintended pregnancy than those who delay getting an IUD by several weeks, according to a new study at Oregon Health & Science University.

The findings are published in the June 9 New England Journal of Medicine.

Research has shown that IUDs are safe, highly effective, long-term reversible contraceptives that don't require active use once they've been inserted. IUDs are underused, however, in part because federal policy prohibits physicians from providing contraceptive services at the time of an abortion, the investigators report.

"Immediate use of any contraceptive method after abortion has been linked to a reduced risk of repeat abortion with the immediate use of an IUD being the most effective method for reducing this risk. However, federal policy makes access a challenge, particularly for low-income patients," said Paula Bednarek, M.D., principal investigator and an assistant professor of obstetrics and gynecology in the OHSU School of Medicine.

A primary concern with inserting an IUD immediately after an abortion is the risk of expulsion, or having it falling out. In the study, the researchers found the rate of expulsion after immediate insertion was higher but statistically not inferior to that of delayed insertion.

"Our data add to the growing body of evidence that IUDs are safe and highly effective, and supports expanding access to IUDs to a wider range of women," Bednarek said.

To conduct this research, Bednarek and colleagues enrolled 575 women, ages 18 and older, who requested abortions at Oregon Health & Science University and three other U.S. academic health centers. The women were randomized into two groups: one group received an IUD within 15 minutes of their abortion, and the other group received an IUD two to six weeks later.

At six months, the researchers found the 258 women who immediately received IUDs had no significant adverse affects and no pregnancies, and more than 90 percent of the women were still using the device. Of the 226 women who underwent delayed insertion, there were, likewise, no significant adverse events; however, five of the 226 women became pregnant all were not using IUDs and only 77 percent were using the device at six months.

"A significant number of women who were randomized to the delayed insertion group did not return to get an IUD placed and instead chose a substantially less effective contraceptive method or none at all," explained Bednarek. "Our results show that women who would like to receive an IUD after an abortion, but are asked to make an appointment for a later date, may not return to actually receive the IUD, and, therefore are at higher risk to have another unintended pregnancy."


'/>"/>

Contact: Tamara Hargens-Bradley
hargenst@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Enlarged prostate: Study demonstrates immediate and long-term benefits of laser treatment
2. Immediate treatment can alleviate future back problems
3. Studies identify complications in women undergoing mastectomy and immediate breast reconstruction
4. Study finds more Americans bypassing their personal physician when immediate treatment required
5. Putting focus on immediate health effects may improve weight loss success
6. Universal HIV testing and immediate treatment could reduce but not eliminate HIV/AIDS epidemic
7. Make An Immediate Difference On Earth Day - AquaBella Organic Solutions Will Help - As A Gift
8. doeLegal Delivers Real-Time Analytics for Immediate Electronic Billing Control
9. Mega Stock Picks (megastockpicks.com) Initiates Coverage on FDA Approval for POZEN, Inc.(NasdaqGM: POZN) Drug Vimovo with Immediate Buy Recommendation
10. Justice Department Files for Immediate Relief Regarding Conditions at Conway Human Development Center, in Conway, Arkansas
11. Anthem Blue Crosss Announcement That It Will Temporarily Suspend a 39% Health Insurance Rate Increase Should Not Deter Immediate Legislative Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology: